A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis
about
Treatment with disease modifying drugs for people with a first clinical attack suggestive of multiple sclerosisAdverse effects of immunotherapies for multiple sclerosis: a network meta-analysisImmunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysisCurrent Evidence for a Role of the Kynurenine Pathway of Tryptophan Metabolism in Multiple SclerosisLaquinimod in the treatment of multiple sclerosis: a review of the data so farOptimizing treatment success in multiple sclerosisRemyelination Therapy in Multiple SclerosisPharmacological Approaches to Delaying Disability Progression in Patients with Multiple SclerosisNF-κB Pathways in the Pathogenesis of Multiple Sclerosis and the Therapeutic ImplicationsRole of the immunogenic and tolerogenic subsets of dendritic cells in multiple sclerosisPrimary progressive multiple sclerosis: current therapeutic strategies and future perspectivesAlemtuzumab for the treatment of relapsing-remitting multiple sclerosis: a review of its clinical pharmacology, efficacy and safety.Treating relapsing-remitting multiple sclerosis: therapy effects on brain atrophy.Laquinimod (ABR-215062) for the treatment of relapsing multiple sclerosis.Laquinimod in the treatment of relapsing remitting multiple sclerosis.A pharmacogenetic signature of high response to Copaxone in late-phase clinical-trial cohorts of multiple sclerosis.Dynamic regulation of serum aryl hydrocarbon receptor agonists in MSDefining a role for laquinimod in multiple sclerosis.Laquinimod, an up-and-coming immunomodulatory agent for treatment of multiple sclerosis.Multiple sclerosis: overview of disease-modifying agentsRole and therapeutic value of dendritic cells in central nervous system autoimmunity.Oral disease-modifying therapies for multiple sclerosis.The meninges: new therapeutic targets for multiple sclerosis.Immune parameters of patients treated with laquinimod, a novel oral therapy for the treatment of multiple sclerosis: results from a double-blind placebo-controlled study.A Network Meta-Analysis of Efficacy and Evaluation of Safety of Subcutaneous Pegylated Interferon Beta-1a versus Other Injectable Therapies for the Treatment of Relapsing-Remitting Multiple SclerosisLaquinimod efficacy in relapsing-remitting multiple sclerosis: how to understand why and if studies disagree.A regional consensus recommendation on brain atrophy as an outcome measure in multiple sclerosis.Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis.S100A12 and the S100/Calgranulins: Emerging Biomarkers for Atherosclerosis and Possibly Therapeutic Targets.Laquinimod dampens hyperactive cytokine production in Huntington's disease patient myeloid cells.Treatment of spontaneous EAE by laquinimod reduces Tfh, B cell aggregates, and disease progression.Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptorLaquinimod Safety Profile: Pooled Analyses from the ALLEGRO and BRAVO Trials.A critical appraisal of daclizumab use as emerging therapy in multiple sclerosis.Oral drugs in multiple sclerosis therapy: an overview and a critical appraisal.The Latest Innovations in the Drug Pipeline for Multiple Sclerosis.The Use of Oral Disease-Modifying Therapies in Multiple Sclerosis.Failed, interrupted and inconclusive trials on relapsing multiple sclerosis treatment: update 2010-2015.The future of multiple sclerosis treatments.Further understanding of the immunopathology of multiple sclerosis: impact on future treatments.
P2860
Q24185806-88D7D02B-8046-462C-81BB-E3C19071E3D5Q24185820-0693398E-A9C4-445C-962D-B53D49D5DBE2Q24187126-C7FC4419-2748-41E8-B208-298189ECCA1DQ26740330-78F353A4-95F5-4510-A45E-1A723906CF8EQ26752895-6B344FD7-1635-4013-BB45-90A73ED7BF08Q26771968-E6A2C5A4-0458-4091-9556-CFB28F5FDD67Q26772359-064BBCBE-1E60-40AD-BE31-4D1FCA568088Q27000269-AAD33350-F13E-456A-A648-38F3E99BD5EBQ28078299-83C4D50B-55D2-496A-91A6-5E4A49313A40Q28082878-B9551507-0E62-445C-8FE5-FB3618EE8CC7Q29030703-3212B55E-9151-4023-BE84-FF06C190B8FBQ30458930-BB2D0160-C102-4755-89C1-5A1457894DDBQ30965003-73D171D5-945D-4DD2-8151-B15E76426285Q31017620-7DEFCC62-2620-4459-8558-0AD221577911Q31080085-B5653856-F40E-47AF-9F5F-543DD8672078Q33742905-78000691-C0CA-4127-A679-10F4DCF4B3E3Q33808285-13CAB9AF-19F3-42A0-8964-A19F9D6B4B9FQ33847350-84FA88A4-7AFB-4038-BB2F-0611DEBA2908Q34332609-92E7E420-1527-45DB-B24A-FAC8B7EFA2B1Q34342662-A4DB8A38-168C-40D0-ADC0-73BF1B224139Q34924088-9D397D9C-E28F-485B-8077-9EF26D4E0C10Q34996562-B3173701-C639-409D-A379-225227E260D2Q35584727-0F60A960-7C53-400D-983C-6E1E23643B24Q35648000-0A8FD814-8984-4765-8E98-4D40B16506DEQ35651621-9B6FC2A8-046B-436D-B82D-30953A4C61EEQ36136472-2D063F96-3F78-4FDB-BA0F-BFE9CF040240Q36202826-80A4774B-6BF0-4106-A5AF-F8A5A9DF5B70Q36475759-F74A55ED-1D9F-4803-9FE4-50D3D4B7BD36Q36631781-788982C2-116C-4F53-9C96-2BCFC3A36746Q37169655-7A64A505-AE7F-4BB2-A499-3B49C5C26276Q37274895-250BE181-125A-41E8-B3E7-E644DF8105C9Q37346761-F235A68F-C75B-411C-822B-9C171FECC469Q37650035-1164D390-1ECA-46A5-91B9-559EAAE816FDQ38397484-ACF347A6-B76E-46D0-8DB8-2A0ED437222CQ38534132-5A97DC14-3478-4F70-BCCD-B9F880DFAA9BQ38678739-EFC81CDB-8523-40BD-9D08-8D6BF44CE3D2Q38761495-49EE3FAF-02EA-48C7-B439-1465A2C4C0C8Q38801807-5B36E998-2678-483B-8C16-403B73D658CBQ38808485-8453F1A5-F62F-4F1E-979E-39865A4910A3Q38837294-748D9EA5-E0BD-4FBB-BD92-C14A0BD20AEF
P2860
A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis
description
im April 2014 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 18 February 2014
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована у квітні 2014
@uk
name
A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis
@en
A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis
@nl
type
label
A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis
@en
A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis
@nl
prefLabel
A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis
@en
A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis
@nl
P2093
P1433
P1476
A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis
@en
P2093
BRAVO Study Group
D L Arnold
E Havrdova
T L Vollmer
Y Gilgun-Sherki
P2888
P304
P356
10.1007/S00415-014-7264-4
P407
P577
2014-02-18T00:00:00Z